Noxopharm (ASX: NOX) is pleased to release its 2019 Annual Report.
This has been an important year for Noxopharm with new trial data continuing to indicate positive clinical benefits of its front-line drug candidate, Veyonda®, in late-stage prostate cancer, pointing to its potential to become an important new drug in both that and other cancers.
For more information, download the attached PDF.
Download this document
